Management of Fibromuscular Dysplasia

Initial Medical Management

The European Society of Cardiology recommends percutaneous transluminal renal angioplasty (PTRA) without stenting as the treatment of choice for symptomatic renal artery fibromuscular dysplasia, while all patients should receive medical blood pressure management and antiplatelet therapy 1, 2
All patients with fibromuscular dysplasia require medical therapy as the foundation of treatment, regardless of whether they undergo revascularization, according to the European Heart Journal 1, 2
Start antiplatelet therapy (aspirin or clopidogrel) to prevent thromboembolic complications in all patients with FMD, as recommended by the European Heart Journal 3
Initiate blood pressure control with RAS blockers (ACE inhibitors or ARBs) as first-line agents when percutaneous intervention is not immediately feasible, as suggested by the European Heart Journal 1, 2
Monitor renal function carefully when using RAS blockers, particularly in bilateral stenoses or solitary functioning kidney, as acute renal failure can occur, according to the European Heart Journal 1
Alternative antihypertensive agents include calcium channel blockers (dihydropyridine or non-dihydropyridine) and alpha-receptor antagonists if RAS blockers are contraindicated, as recommended by the European Heart Journal 4

Revascularization Strategy for Renal Artery FMD

PTRA without stenting should be considered for patients with hypertension and hemodynamically significant renal artery stenosis due to FMD (Class IIa recommendation), according to the European Heart Journal 1, 2
Avoid stenting as first-line therapy; reserve stents only for dissection or balloon angioplasty failure, as recommended by the European Heart Journal 2, 3
Perform procedures in experienced centers due to technical complexity and risk of complications, as suggested by the European Heart Journal 1
Consider open surgical revascularization only when endovascular therapy is technically unfeasible, has failed, or for complex aneurysms and lesions involving arterial bifurcations, according to the European Heart Journal 1, 2

Cerebrovascular FMD Management

Carotid angioplasty with or without stenting is reasonable for patients with retinal or hemispheric cerebral ischemic symptoms related to FMD of the ipsilateral carotid artery (Class IIa recommendation), as recommended by the European Heart Journal 3
Do not revascularize asymptomatic carotid FMD, regardless of stenosis severity (Class III recommendation), according to the European Heart Journal 3

Systemic Disease Surveillance

FMD is a systemic arterial disease requiring comprehensive vascular evaluation, as suggested by the European Heart Journal 1, 2, 3
Perform CT or MRI angiography from head to pelvis at diagnosis to identify involvement in multiple vascular beds, particularly carotid, vertebral, renal, and iliac arteries, according to the European Heart Journal 4, 2
Annual non-invasive imaging of carotid arteries is reasonable initially to detect disease progression or new lesions (Class IIa recommendation), as recommended by the European Heart Journal 2, 3
Reduce imaging frequency once stability has been confirmed over time, as suggested by the European Heart Journal 2
Screen for aneurysms as they represent a potential complication requiring surveillance or intervention, according to the European Heart Journal 2

Diagnostic Workup

Duplex ultrasonography as initial screening (Class I recommendation), as recommended by the European Heart Journal 2, 3
CT angiography or MR angiography for comprehensive screening (Class I recommendation), according to the European Heart Journal 2, 3
Catheter angiography as the gold standard when clinical suspicion is high and noninvasive tests are inconclusive, as suggested by the European Heart Journal 2, 3
Do not use captopril renal scintigraphy, selective renal vein renin measurements, or plasma renin activity for screening (Class III recommendation), according to the European Heart Journal 2, 3
Assess for very elevated renin levels which raise suspicion for renovascular hypertension, as recommended by the European Heart Journal 4, 2

Critical Pitfalls to Avoid

Never use stents as first-line therapy for renal FMD—balloon angioplasty alone is superior, as recommended by the European Heart Journal 2, 3
Never assume isolated disease—always evaluate multiple vascular beds as FMD is systemic, according to the European Heart Journal 1, 3
Never revascularize asymptomatic carotid lesions—medical management is appropriate, as suggested by the European Heart Journal 3
Monitor renal function closely when using RAS blockers in bilateral disease to prevent acute kidney injury, according to the European Heart Journal 1, 2
Control blood pressure aggressively to prevent arterial dissection, which can occur in multiple vascular territories, as recommended by the European Heart Journal 1

Long-term Management

Regular blood pressure monitoring and renal function assessment in all patients with renal artery FMD, as suggested by the European Heart Journal 3
Refer to specialized centers for dedicated multidisciplinary FMD management, according to the European Heart Journal 3

Management of Fibromuscular Dysplasia

Foundation: Universal Medical Therapy for All Patients

The American Heart Association recommends that all patients with fibromuscular dysplasia require antiplatelet therapy and blood pressure control as the cornerstone of management, regardless of whether they undergo revascularization 5

Renal Artery FMD: When to Intervene

The American College of Cardiology suggests that refractory hypertension despite medical management, worsening renal function, and recent onset hypertension in young patients are indications for revascularization 6

Cerebrovascular FMD: Symptom-Driven Strategy

The American Heart Association recommends that for patients with stroke or TIA attributable to FMD, antiplatelet therapy is the primary treatment; carotid angioplasty may be reasonable for recurrent ischemic events despite optimal medical management 5
The American Stroke Association suggests that antiplatelet therapy is reasonable for patients with dissection and FMD but no intraluminal thrombus, over anticoagulation 5
The American Heart Association recommends that carotid angioplasty with or without stenting be considered for recurrent ischemic stroke without other attributable causes despite optimal medical management 5

Management of Fibromuscular Dysplasia

Diagnostic Evaluation and Treatment

Obtain a morning plasma aldosterone and plasma renin activity to screen for primary aldosteronism, as resistant hypertension is common in FMD, according to the Hypertension guideline society 7
Consider percutaneous transluminal renal angioplasty without stenting if worsening renal function occurs, as recommended by the Hypertension guideline society 7
Consider percutaneous transluminal renal angioplasty without stenting if recent onset hypertension in a young patient is present, with an audible bruit, as recommended by the Hypertension guideline society 7

Fibromuscular Dysplasia: Key Cited Evidence

Epidemiology and Clinical Presentation

Fibromuscular dysplasia (FMD) is a non‑atherosclerotic, non‑inflammatory arterial disease that predominantly affects middle‑aged women and most commonly presents with hypertension due to renal artery involvement or neurological symptoms from cerebrovascular disease. 8, 9, 10

Neurological Manifestations

In patients with cerebrovascular FMD, ischemic stroke or transient ischemic attack can occur secondary to reduced cerebral blood flow or thromboembolism. 8, 9
Carotid or vertebral artery dissection may arise spontaneously in individuals with FMD, contributing to neurological deficits. 8, 9
Horner syndrome can result from sympathetic chain involvement secondary to carotid artery FMD. 8, 9
Cranial nerve palsies are reported in FMD affecting the skull‑base arteries. 8, 9
Subarachnoid hemorrhage may occur in FMD patients due to rupture of associated intracranial aneurysms. 8, 9

Imaging Findings

Arterial elongation, kinking, and coiling are characteristic imaging findings observed in FMD across multiple vascular territories. 8, 9

Medical Management

Antiplatelet therapy (aspirin or clopidogrel) is recommended for all patients with FMD, including those who are asymptomatic, to reduce thromboembolic risk. 8, 9
For asymptomatic carotid FMD, antiplatelet therapy combined with serial imaging is advised rather than revascularization. 8, 9

Revascularization Outcomes

Both surgical revascularization and endovascular techniques have been successful in alleviating ischemic symptoms in symptomatic cerebrovascular FMD. 8, 9

Association with Cervical Artery Dissection

Approximately 15 % of patients with FMD develop cervical artery dissection, highlighting a notable association. 8, 9, 10

Balloon Angioplasty as First‑Line Therapy for Renal Fibromuscular Dysplasia

Primary Endovascular Strategy

Balloon angioplasty without stenting is the definitive first‑line treatment for symptomatic renal artery stenosis caused by fibromuscular dysplasia (FMD). This is a Class I recommendation with Level B evidence from the ACC/AHA and ESC guidelines. [11][12]
Pathophysiology supports balloon‑only therapy: FMD lesions are non‑inflammatory, non‑atherosclerotic arterial abnormalities that respond well to mechanical dilation and typically remain patent after angioplasty, unlike atherosclerotic ostial lesions that are prone to elastic recoil. [11][13]

Bailout Stenting Criteria

Stent placement is reserved for bailout situations only, specifically arterial dissection that occurs during balloon angioplasty. This strategy is endorsed by both ACC/AHA and ESC guidelines. [14][11][12][13]

Procedural Outcomes (Endovascular)

Major complication rate after balloon angioplasty for renal FMD is approximately 6.3 %.
Procedure‑related mortality is about 0.9 %. These low rates contrast with higher complication and mortality rates reported for surgical revascularization. 14

Comparison with Surgical Revascularization

Open surgical reconstruction for renal FMD carries a major complication rate of ~15.4 % and a mortality rate of ~1.2 %, substantially worse than endovascular balloon angioplasty. 12

Distinction from Atherosclerotic Renal Artery Stenosis

In atherosclerotic ostial lesions, balloon angioplasty alone achieves only ~63 % procedural success versus ~90 % with primary stenting.
Restenosis occurs in ~48 % of balloon‑only cases compared with ~14 % when stents are used.
Aorto‑ostial atherosclerotic plaques are prone to elastic recoil, justifying primary stenting in this setting. [14][11]

Common Pitfalls to Avoid

Primary stenting of FMD lesions is not recommended; it adds unnecessary hardware, cost, and potential long‑term complications without improving outcomes. [11][12]
Do not intervene on all “beaded” renal arteries; treatment is limited to symptomatic FMD with evidence of organ ischemia (e.g., uncontrolled hypertension or declining renal function). 12
Procedures should be performed in experienced centers because of technical complexity and the need for appropriate bailout strategies. 12

Indications for Surgical Revascularization

Open surgical reconstruction is reserved for complex aneurysms associated with FMD and for cases requiring ex‑vivo reconstruction of complex disease. [11][14]
In patients younger than 21 years, internal iliac artery grafts are preferred over vein grafts to reduce the risk of late aneurysmal degeneration. 14